Pre-clinically, two in vitro/ex vivo tests provided early evidence of safe administration of MOv18 IgE in patients with cancer: a mast cell degranulation assay conducted in the presence of serum from ovarian cancer patients, and the Basophil Activation Test (BAT), conducted in whole unfractionated human blood, an emerging clinical tool used in allergy, to evaluate propensity for type I hypersensitivity to different allergens oncology therapeutic agents such as chemotherapies and therapeutic antibodies. Here, IGHE is linked to ovarian cancer.